

Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/T79F913CB2C2EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: T79F913CB2C2EN

Abstracts

The 7 major thalassemia markets reached a value of US\$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The thalassemia market has been comprehensively analyzed in IMARC's new report titled "Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thalassemia refers to a genetic blood disorder that primarily affects the production of hemoglobin, a protein found in red blood cells responsible for carrying oxygen throughout the body. There are two main types of the ailment: alpha thalassemia and beta thalassemia. The symptoms of the disease can vary depending on the type and severity of the condition. Individuals with thalassemia may experience fatigue, weakness, shortness of breath, pale or yellowish skin, delayed growth and development, an enlarged spleen, etc. In more severe cases, the disorder can cause bone deformities, anemia, and damage to various organs, such as the heart and liver. Thalassemia is diagnosed through a combination of medical history, physical examination, and laboratory tests. A complete blood count (CBC) can reveal low levels of red blood cells and hemoglobin, which are typical indicators of the ailment. Additionally, a hemoglobin electrophoresis test can determine the specific type of thalassemia present. Genetic testing can also be done to confirm the diagnosis and identify carriers of the disease.

The increasing cases of mutations in genes that control the production of hemoglobin in the body are primarily driving the thalassemia market. In addition to this, the rising usage of certain medications, such as erythropoietin and androgens, to stimulate the formation of red blood cells in the bone marrow and alleviate symptoms of anemia in

thalassemia patients, is creating a positive outlook for the market. Moreover, the escalating utilization of stem cell transplantation for restoring normal hemoglobin production in the body, thereby eliminating the need for blood transfusions, is also augmenting the market growth. Besides this, the widespread adoption of hemoglobin electrophoresis for diagnosis, since it can determine the quantity of each hemoglobin variant present, which can help to further classify the type and severity of thalassemia, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of various oral iron chelators, including deferoxamine, deferitron, deferiprone, etc., that preferentially chelate the iron in the heart to lower the risk of thalassemia, is also bolstering the market growth. Furthermore, the inflating utilization of several novel medications, such as hydroxyurea and L-glutamine, which aid in lowering the symptoms of the ailment by increasing the production of fetal hemoglobin, is expected to drive the thalassemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the thalassemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thalassemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thalassemia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thalassemia market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the thalassemia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current thalassemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the thalassemia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the thalassemia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the thalassemia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of thalassemia across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of thalassemia by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of thalassemia by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of thalassemia by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with thalassemia across the seven major markets?

What is the size of the thalassemia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of thalassemia?

What will be the growth rate of patients across the seven major markets?

Thalassemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for thalassemia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thalassemia market?

What are the key regulatory events related to the thalassemia market?

What is the structure of clinical trial landscape by status related to the thalassemia market?

What is the structure of clinical trial landscape by phase related to the thalassemia market?

What is the structure of clinical trial landscape by route of administration related to the thalassemia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 THALASSEMIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 THALASSEMIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 THALASSEMIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 THALASSEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 THALASSEMIA - UNMET NEEDS

10 THALASSEMIA - KEY ENDPOINTS OF TREATMENT

11 THALASSEMIA - MARKETED PRODUCTS

- 11.1 List of Thalassemia Marketed Drugs Across the Top 7 Markets

11.1.1 Reblozyl (Luspatercept) - Acceleron Pharma/Celgene Corporation

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

11.1.2 Zynteglo (Betibeglogene autotemcel) - bluebird bio

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

11.1.3 Exjade (Deferasirox) - Novartis

- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets

11.1.4 Ferriprox (Deferiprone) - Apotex

- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 THALASSEMIA - PIPELINE DRUGS

12.1 List of Thalassemia Pipeline Drugs Across the Top 7 Markets

12.1.1 Mitapivat - Agios Pharmaceuticals

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 SLN 124 - Silence Therapeutics plc

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action

- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 CTX001 - Vertex Pharmaceuticals/ CRISPR Therapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Etavopivat - Forma therapeutics
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 EDIT-301 - Editas Medicine, Inc.
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. THALASSEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. THALASSEMIA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 THALASSEMIA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Thalassemia - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Thalassaemia - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Thalassaemia - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Thalassaemia - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Thalassaemia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Thalassaemia - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Thalassaemia - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Thalassaemia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Thalassaemia - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Thalassaemia - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Thalassaemia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Thalassaemia - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Thalassaemia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Thalassaemia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Thalassaemia - Market Size

- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Thalassaemia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Thalassaemia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Thalassaemia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Thalassaemia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Thalassaemia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Thalassaemia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Thalassaemia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Thalassaemia - Access and Reimbursement Overview

16 THALASSEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 THALASSEMIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 THALASSEMIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/T79F913CB2C2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T79F913CB2C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

